TrialAlzheimer's research & therapy2022

Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.

Eric McDade et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.